- Home
- Companies
- canada saskatchewan
- protein targeting
Show results for
Refine by
Protein Targeting Suppliers Serving Canada Saskatchewan
30 companies found
based inPhoenix, ARIZONA (USA)
Ordinatrix builds on over a decade of development and refinement of the Nucleic Acid Programmable Protein Arrays (NAPPA) technology. Ordinatrix provides a customizable solution for analysis of the proteome with the commercial introduction of the ...
based inIrvine, CALIFORNIA (USA)
Established in 1997 by a group of renowned scientists, GeneTex's corporate mission remains clear. While commercial polyclonal and monoclonal antibodies have driven progress in science and medicine since their introduction, the generation of reliable ...
based inVannas, SWEDEN
Agrisera is a Swedish company, established in 1985, specialized in antibody production and purification. Since 2020, Agrisera is a part of Olink Group. Agrisera provides off-the-shelf antibodies for plant and algal research, with prompt delivery ...
The Rubisco quantitation kit is suitable for quantitation of Rubisco in plant and algal samplesusing quantitative immunoblotting. It contains anti-RbcL antibody, Rubisco protein standard and theProtein Extraction Buffer for quantitative protein ...
based inCambridge, UNITED KINGDOM
Nuclera is the pioneer in bringing rapid protein prototyping to the benchtop. We make proteins accessible through eProtein DiscoveryTM. Through our technology, we accelerate breakthrough improvements in human health and empower life science ...
based inMalvern, DELAWARE (USA)
Founded in 1996, LifeSensors, Inc. helps life scientists innovate in basic research, drug discovery and diagnostics. LifeSensors pioneered the SUMO-fusion system for high quality protein expression. Development of cutting-edge tools for ubiquitin ...
Ubiquitin is a small polypeptide that is conjugated via its C-terminus to an ε-amino group of lysine on a target protein; this conjugation is referred to as monoubiquitylation. Subsequently, additional ...
based inSan Diego, CALIFORNIA (USA)
Aviva Systems Biology provides our customers with an extensive collection of quality antibodies for research and diagnostic applications. Aviva currently offers antibodies to more than 7,000 different protein targets due to our high throughput ...
Aviva provides customized solutions to each protein expression project. Our expert scientific staff has experience with difficult proteins and have produced more than 2,500 recombinant proteins. Whether your needs are small scale research or large ...
based inParis, FRANCE
The Bioprojet company was founded in 1982 under the impetus of Jeanne-Marie Lecomte and Jean-Charles Schwartz, doctors of pharmacy and sciences. From very different backgrounds, Jeanne-Marie Lecomte made her career in the pharmaceutical industry, ...
based inPortland, OREGON (USA)
HTI accelerates drug discovery for Biotech and Pharma companies by providing structure determination services using cryogenic-electron microscopy (cryo-EM) and machine learning based image processing software. As a member of the Oregon Bioscience ...
Cryo-EM is a powerful technology for determining high-resolution 3D structures of biological macromolecules and bound compounds. It is complementary to X-ray crystallography, NMR, and other biophysical ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
The process where proteins separated by electrophoresis are transferred or “blotted” from the gel matrix onto a membrane (usually nitrocellulose or polyvinylidene difluoride (PVDF)), followed by subsequent antibody-based detection on the membrane ...
based inSeoul, SOUTH KOREA
PROTIA Inc. aims to contribute to human health and well-being through finding new protein targets for disease prediction, early diagnosis, and development of new medicines. Based on our dedication for identification of bio-markers needed in early ...
based inMadison, WISCONSIN (USA)
BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas where there is a strong need but a ...
AptaFluor SAH Methyltransferase Assay directly measures SAH produced by methyltransferase enzymes during methylation. These enzymes methylate a variety of substrates using S-adenosylmethionine (SAM) as the methyl donor, leaving the common ...
based inMartinsried, GERMANY
Proteros is a Munich-based provider of structure-based early stage drug discovery services with a cutting-edge discovery engine tailored to unlock even the most technically challenging drug targets. Proteros supports its clients to reach the right ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against ...
based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic ...
With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug ...
based inMilford, MASSACHUSETTS (USA)
Waters Corporation has been in the business of making innovative analytical instruments that assist scientists in reaching their scientific goals, increase productivity, and earn laboratory-based organizations a higher return on their investments in ...
based inVictoria, BRITISH COLUMBIA (CANADA)
Aurinia exists to make a difference. Our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease. From the earliest days of the company, we’ve applied a creative, thoughtful and responsible ...
AUR200 is a recombinant Fc fusion protein designed to specifically block B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand, known as APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to ...
based inPrinceton, NEW JERSEY (USA)
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services. ...
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much ...
based inHalle, GERMANY
Navigo Proteins is a successful and steadily growing, privately held protein engineering company, which develops best-in-class custom precision affinity ligands, based on selected protein scaffolds. We partner with pharma, biotech and life science ...
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both ...